3 takeaways from cancer's biggest conference

This year's iteration of the American Society of Clinical Oncology's annual meeting may have been quieter — Merck & Co. and Bristol-Myers Squibb skipped out on holding their regular investor briefings — yet still showcased the breadth of investment from biotech and pharmaceutical companies into new cancer drugs.

Miss the conference? Here are three takeaways from ASCO this year.